Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

Imagem de Miniatura
Arquivos
art_GUDIOL_Coinfections_and_superinfections_complicating_COVID19_in_cancer_patients_2021.PDF (420.55 KB)
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
W B SAUNDERS CO LTD
Autores
GUDIOL, C.
DURA-MIRALLES, X.
AGUILAR-COMPANY, J.
HERNANDEZ-JIMENEZ, P.
MARTINEZ-CUTILLAS, M.
FERNANDEZ-AVILES, F.
MACHADO, M.
VAZQUEZ, L.
MARTIN-DAVILA, P.
CASTRO, N. de
Citação
JOURNAL OF INFECTION, v.83, n.3, p.306-313, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with COVID-19. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted at least 48 h were included in the analysis of superinfections. Results: 684 patients were included (384 with solid tumors and 300 with hematological malignancies). Co-infections and superinfections were documented in 7.8% (54/684) and 19.1% (113/590) of patients, respectively. Lower respiratory tract infections were the most frequent infectious complications, most often caused by Streptococcus pneumoniae and Pseudomonas aeruginosa. Only seven patients developed opportunistic infections. Compared to patients without infectious complications, those with infections had worse outcomes, with high rates of acute respiratory distress syndrome, intensive care unit (ICU) admission, and case-fatality rates. Neutropenia, ICU admission and high levels of C-reactive protein (CRP) were independent risk factors for infections. Conclusions: Infectious complications in cancer patients with COVID-19 were lower than expected, affecting mainly neutropenic patients with high levels of CRP and/or ICU admission. The rate of opportunistic infections was unexpectedly low. The use of empiric antimicrobials in cancer patients with COVID-19 needs to be optimized. (C) 2021 The Authors.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/42248
Referências
  1. Acuna-Villaorduna A., 2020, CANCER DISCOV, V10, P935, DOI [DOI 10.1158/2159-8290.CD-20-0516, 10.1158/2159-8290.CD-20-0516]
  2. Agrifoglio A, 2020, J MYCOL MED, V30, DOI 10.1016/j.mycmed.2020.101012
  3. Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
  4. Borman AM, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02136-20
  5. Chen Z., 2020, CANCER DISCOV, V10, P783, DOI [10.1158/2159-8290.CD-20-0422, DOI 10.1158/2159-8290.CD-20-0422]
  6. Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008
  7. Falcone M, 2021, J ANTIMICROB CHEMOTH, V76, P1078, DOI 10.1093/jac/dkaa530
  8. Fekkar A, 2021, AM J RESP CRIT CARE, V203, P307, DOI 10.1164/rccm.202009-3400OC
  9. Garcia-Vidal C, 2021, CLIN MICROBIOL INFEC, V27, P83, DOI 10.1016/j.cmi.2020.07.041
  10. Gudiol C, 2013, CLIN MICROBIOL INFEC, V19, P474, DOI 10.1111/j.1469-0691.2012.03879.x
  11. Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
  12. Hughes S, 2020, CLIN MICROBIOL INFEC, V26, P1395, DOI 10.1016/j.cmi.2020.06.025
  13. Karaba SM, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofaa578
  14. Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
  15. Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
  16. Machado M, 2021, MYCOSES, V64, P132, DOI 10.1111/myc.13213
  17. Mastrangelo Andrea, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1594
  18. Mitaka H, 2021, MYCOSES, V64, P993, DOI 10.1111/myc.13292
  19. Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
  20. Musuuza JS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251170
  21. Nucci M, 2021, MYCOSES, V64, P152, DOI 10.1111/myc.13225
  22. Passamonti F, 2020, LANCET HAEMATOL, V7, pE737, DOI 10.1016/S2352-3026(20)30251-9
  23. Pinato DJ, 2020, CANCER DISCOV, V10, P1465, DOI 10.1158/2159-8290.CD-20-0773
  24. Raad I, 2007, EUR J CLIN MICROBIOL, V26, P549, DOI 10.1007/s10096-007-0320-6
  25. Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
  26. Salmanton-Garcia J, 2021, EMERG INFECT DIS, V27, P1077, DOI 10.3201/eid2704.204895
  27. Shah GL, 2020, J CLIN INVEST, V130, P6656, DOI 10.1172/JCI141777
  28. Smith Leigh, 2021, Infect Control Hosp Epidemiol, P1, DOI 10.1017/ice.2021.148
  29. Sogaard KK, 2021, J INTENSIVE CARE, V9, DOI 10.1186/s40560-021-00526-y
  30. Zhang H, 2021, JNCI-J NATL CANCER I, V113, P371, DOI 10.1093/jnci/djaa168

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - LIM/37
Artigos e Materiais de Revistas Científicas - ODS/03